Reporter brief
Safer mTOR Inhibition for Human Geroprotection
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No results are available; this describes study design only, not findings
- The study is limited to 6 weeks of treatment, too short to assess effects on aging endpoints
- Recruitment of disease-free older adults may not represent the broader aging population or those with common age-related conditions
Study design and sample
Rct; Human.
Participants aged 55-89 years old that are free of overt chronic diseases
- Design
- Rct
- Sample
- —
- Journal
- University of Wisconsin, Madison
- Published
- May 28, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.